CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 146 enrolled
Drug / intervention
Meclizine +2 moredrug
Likely dose
Nicotine Patch 21mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01443858
NCT01443858Phase 2Completed
CompareCT.gov

Meclizine as a Potential Smoking Cessation Treatment

Duke University·interventional·Posted Sep 30, 2011·Updated Aug 1, 2014

In Brief

A Phase 2 clinical trial evaluating Meclizine, Nicotine Patch, and 1 other intervention for Smoking Cessation. Completed, enrolled 146 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate whether meclizine, an antihistamine used to prevent or treat motion sickness, can help smokers quit smoking. This study will also investigate the potential relationship between genes you have inherited and success in quitting smoking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsPhilip Morris USA, Inc.

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 30, 2011
Enrollment StartAug 1, 2011
Primary CompletionDec 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.8 years ago

Interventions

Meclizinedrug

Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.

Nicotine Patchdrug

Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily. Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.

Placebodrug

Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.